HK-listed gold stocks jump as US economic fears boost bullion prices
LOS ANGELES - Niagen Bioscience, Inc. (NASDAQ: NAGE), a company specializing in NAD+ science and healthy aging, has announced the appointment of Dr. Pinchas Cohen to its Scientific Advisory Board. The company, which has demonstrated strong financial health with a current ratio of 3.57 and revenue growth of 19.2% over the last twelve months, continues to strengthen its leadership team. Dr. Cohen, a prominent figure in gerontology and mitochondrial biology, joins the board with a wealth of experience, including his current roles as Dean of the University of Southern California Leonard Davis School of Gerontology and Distinguished Professor.
The addition of Dr. Cohen is seen as a significant move for Niagen Bioscience, as the company continues to focus on advancing research in NAD+ and its influence on healthspan. His expertise is expected to provide valuable insights into the company’s ongoing efforts to develop solutions for aging-related diseases.
Dr. Cohen’s scientific contributions include over 350 published papers and the discovery of several novel microproteins, such as MOTS-c and SHLP, which have potential applications in precision medicine for various age-related conditions. He has also founded two biotech companies and received numerous accolades in his field, including the NIH Director’s Transformative Research Award.
Upon his appointment, Dr. Cohen expressed his honor in joining the advisory board and commended Niagen Bioscience for their commitment to rigorous scientific research. CEO Rob Fried expressed excitement about learning from Dr. Cohen’s expertise in mitochondrial and longevity research.
Niagen Bioscience, previously known as ChromaDex Corp., is recognized for its pioneering work in the field of NAD+, a vital coenzyme that plays a crucial role in cellular health and declines with age. The company’s product portfolio includes Tru Niagen®, a leading oral supplement for boosting NAD+ levels, and Niagen Plus™, which offers pharmaceutical-grade intravenous and injectable products.
This announcement is based on a press release statement and reflects the company’s ongoing dedication to collaborating with top scientists to improve human health through innovative research in NAD+. The company’s stock has shown remarkable momentum, with a 114% return over the past year and is scheduled to report earnings on May 7th. According to InvestingPro analysis, which offers 15+ additional insights about NAGE, the stock currently trades above its Fair Value. Investors seeking detailed financial analysis and comprehensive research reports for NAGE and 1,400+ other stocks can access them through InvestingPro’s premium service.
In other recent news, Niagen Bioscience has maintained its stability amid global tariffs, with its operations and supply chain remaining unaffected due to its strategic decision to manufacture its products entirely in the United States. This move has allowed the company to avoid disruptions typically associated with international trade volatility. Additionally, H.C. Wainwright reaffirmed its Buy rating on Niagen Bioscience, setting a price target of $11.00, citing the company’s resilience and potential growth opportunities in expanding its nicotinamide riboside (NR) products beyond nutritional supplements. The firm expressed optimism about the company’s future, particularly in exploring new markets for its NR franchise.
Niagen Bioscience has also expanded its intellectual property portfolio with a new U.S. patent for various forms of NR salts, which strengthens its market position in NAD+ precursors. This patent, licensed from Queen’s University Belfast, provides exclusive rights to NR salt forms until 2034, bolstering the company’s competitive edge. The company recently rebranded from ChromaDex Corp. to Niagen Bioscience, aligning its corporate identity with its flagship ingredient, Niagen. This rebranding reflects the company’s commitment to advancing healthspan through NAD+-boosting solutions.
International sales, accounting for approximately 24% of the company’s revenue in 2024, remain stable, with over 12% coming from Hong Kong, a market unaffected by tariffs. The company’s robust patent portfolio, protecting over 90 patents related to Niagen, ensures its leadership in the healthy aging sector. Niagen Bioscience’s CEO, Rob Fried, has expressed confidence in maintaining product delivery and price stability, further solidifying the company’s position in the market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.